Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Level zero healthThe beginning of a medical device set up by a woman, which aims to break a new ground by developing a device for continuous hormone monitoring, has closed a $ 2.9 million in a pre-annual financing tour. You need the start, invasive blood boots and support research, such as individual doses for hormone-based contraception, or even new treatment for new health updates.
“One of our investors, there are companies that are building companies, and the children are creating a new technology here,” he said, “said Co-founder and CEO Ula Rustamova discuss the company’s development after discussing the company’s development Last fall When you submit on stage in TechCrunch, when the starting battlefield contest is a part of the competition.
“The goal is to create a completely new marketplace, does it? The CGMS (continued glucose monitors) were created in the same way. They created a market for a market, almost nothing,” he said. “This is a completely new category of itself, I hope it will inspire people to use the device and information from the device and to have a ripple effect in the next few decades.”
Step by step
Can build a new product category of any stripes. It will not be able to serve a paradigm change in a medical device to start and download a hardware, clear level of zero health, hormones.
Therefore, the team and a single step is a single use product (in the prototype form), hoping to cleanse and support the fertile hormone test for recipe for next year (IVF) and low testosterone (TRT).
The existing prototype consists of small needles that can only take samples under the skin to detect the quantity of prints.
This is a step to monitor the hormone monitoring they hope to bring to the market market – something that can take a sustainable measurement for 2028, estrogen and testosterone, the dress interstitial fluid. (This is a liquid that fills the gaps around the cells, blood plasma and the cells between cells – therefore the biochemical compounds in the blood can be found in the interstisal liquid.)
A continuous hormone monitoring device – or rather, the data he chosen – can play a transformative role in increasing the scientific concept of playing roles in roles – CGMS diabetes managementand more).
However, the level is a business in Zero Health – a B2B business, a B2B business aiming to sell technology to health provider networks – works on the routes of the twin product to shorten the gap between the Time-Market Mission and are currently there.
“We think that this is the source of this truth, which is the interstitial liquid – Rustamova Techcrunch says.” And we think we must start here first, here is a shorter product.
“The idea is that continuously (hormone monitoring) … This is because this is a way, because in a way, this is also in a way that we understand that we will not try to change the protocol on the market today We must log in in the picture and “Let’s try this information and comment” No research question, in fact, it is like finger stick devices, but it is also a patch. “
Prototype can take measurements during the worn day – for use as a woman’s “immediate delivery value”, a number of data points to use as IVFs, a woman can draw a large number of blood to watch in another way.
Rustamova, clinical trials for this single use of the team next year, clinical trials and secured clinical tests and secured clearance to sell a Council of Europe and European health care markets (says he will not be able to come in the first place ).
“Hopefully, we want to have a little connection this year (discovering patch found between hormones can be detected and the levels can be found) – this is the word I want to promise to surrender with the pre-seed money.”
CTO and co-founder Irene Jia, the goal of the team is to show 90% + ratio compared to measuring a hormone level with a blood draw.
Risk vs reward
Although later, it is concerned with the detection of delay and interstitial liquid between blood-based readings, Rustamova to emphasize the difference between CGMS and hormone monitoring. If the risk of diabetes is very high, the hormone monitoring is usually not a high share.
“For glucose, there are potentially deadly results to give a mistake or delay …” It is clear that … here is a very different risk profile. “He also noted that the first in the market The CGMS has made a lower contact with the blood reading of these devices than these devices.
The goal of the proposal is to increase the peace precision. Which – perhaps – the reason for investors’ the beginning of this Medtech starting to the early round – potential awards and risks in a positive risks.
Other – Undoubtedly – a useful factor here Level Zero Health not only focuses on women’s health problems; Monitoring Men’s hormones are the main part of the initial work plan. (And this, the most technological investors are still in the event of those who have bets in solving problems with the interests.)
Level Zero’s health pre-financing tour, Europe VC, REDALPINE headed. HAX (SOSV), Sahibkarlar Birinci (EF) və sənaye mütəxəssisləri də Dairəyə töhfə verdi – SOSV ilə əvvəllər Deeptech / Həcc HAZ HAZ sürətləndirici proqramı və Rüstəmova da EF alumudur.
Commenting in a statement, Philip Dneis, Investor and a level Zero Health Board member, said: “We will do it for blood pressure and one more hormones are one of the sacred plates of diagnosis and fundamental sciences Like, hormone tracking missions have not been more excited to restore tracking missions with their novels, the period of personal health management. “
